上海凯宝 reported revenue of ¥0.46B for the period ended 2026-06-30, -23.4% year on year. Net income was ¥0.10B, a 22.0% net margin on a 80.2% gross margin. The largest revenue line is 针剂 at 92% of the total. Free cash flow for the period was ¥0.06B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.46B | -23.4% |
| Gross profit | ¥0.37B | — |
| Operating income | ¥0.12B | — |
| Net income | ¥0.10B | -16.4% |
| Gross margin | 80.2% | Net margin 22.0% |
| Revenue Q/Q | -36.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| 针剂 | ¥0.43B | 92.1% |
| 胶囊 | ¥0.03B | 5.8% |
| 其他药品 | ¥0.01B | 1.7% |
| 其他(补充) | ¥0.00B | 0.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.09B | 19.8% |
| R&D | ¥0.04B | 8.6% |
| SG&A | ¥0.23B | 48.9% |
| Tax & other | ¥0.02B | 4.3% |
| Item | Amount |
|---|---|
| Total assets | ¥4.59B |
| Total liabilities | ¥0.31B |
| Shareholders' equity | ¥4.29B |
| Equity / assets | 93.3% |
| Operating cash flow | ¥0.06B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.06B |
| Cash conversion (OCF / net income) | 107% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
九洲集团 ・ 回天新材 ・ 朗科科技 ・ 星辉娱乐 ・ *ST赛为 ・ 华力创通 ・ 台基股份 ・ 天源迪科 ・ 合康新能 ・ 福瑞医科 ・ 世纪鼎利 ・ 琏升科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies